1. Nobiletin, an activator of the pyruvate kinase isozyme M1/M2 protein, upregulated the glycolytic signalling pathway and alleviated depressive-like behaviour caused by artificial light exposure at night in zebrafish.
- Author
-
Zhang ML, Li XP, Gao LF, Liu J, Bi ZJ, Miao YH, Shan Y, and Yu HL
- Subjects
- Animals, Behavior, Animal drug effects, Humans, Molecular Docking Simulation, Male, Disease Models, Animal, Antidepressive Agents pharmacology, Antidepressive Agents chemistry, Isoenzymes metabolism, Isoenzymes genetics, Zebrafish, Pyruvate Kinase metabolism, Pyruvate Kinase genetics, Pyruvate Kinase chemistry, Flavones pharmacology, Flavones chemistry, Glycolysis drug effects, Signal Transduction drug effects, Depression drug therapy, Depression metabolism, Depression genetics, Zebrafish Proteins genetics, Zebrafish Proteins metabolism, Light
- Abstract
We established a zebrafish model of depression-like behaviour induced by exposure to artificial light at night (ALAN) and found that nobiletin (NOB) alleviated depression-like behaviour. Subsequently, based on the results of a 24-h free movement assay, clock gene expression and brain tissue transcriptome sequencing, the glycolysis signalling pathway was identified as a potential target through which NOB exerted antidepressant effects. Using the ALAN zebrafish model, we found that supplementation with exogenous L-lactic acid alleviated depressive-like behaviour. Molecular docking and molecular dynamics simulations revealed an inter-molecular interaction between NOB and the pyruvate kinase isozyme M1/M2 (PKM2) protein. We then used compound 3 k to construct a zebrafish model in which PKM2 was inhibited. Our analysis of this model suggested that NOB alleviated depression-like behaviour via inhibition of PKM2. In summary, NOB alleviated depressive-like behaviour induced by ALAN in zebrafish via targeting of PKM2 and activation of the glycolytic signalling pathway., Competing Interests: Declaration of competing interest The authors declare no conflict of interest. This work has not been submitted/published or being submitted to another journal., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2025
- Full Text
- View/download PDF